Christel Renoux1, Sarah Vahey2, Sophie Dell'Aniello2, Jean-François Boivin3. 1. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada2Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada3Department of Epidemiology and Biostatistics, McGill University, Montréal, Québec, Canada. 2. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada. 3. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada3Department of Epidemiology and Biostatistics, McGill University, Montréal, Québec, Canada.
Abstract
Importance: Selective serotonin reuptake inhibitors (SSRIs) may increase the risk for spontaneous intracranial hemorrhage (ICH), an effect that is in theory linked to the strength of inhibition of serotonin reuptake of an antidepressant. However, whether antidepressants that are strong inhibitors of serotonin reuptake actually increase the risk for ICH and the effect of concomitant use of antithrombotics are unknown. Objectives: To assess the risk for ICH associated with the use of SSRIs compared with tricyclic antidepressants (TCAs) among new users of antidepressants and according to the relative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant use of antithrombotics modifies this risk. Design, Setting, and Participants: This population-based cohort study included new users of antidepressants 18 years or older from January 1, 1995, to June 30, 2014. More than 650 general practices in the United Kingdom contributing to the Clinical Practice Research Datalink enrolled patients. with use of a nested case-control approach, each case of a first ICH identified during follow-up was matched with as many as 30 control individuals by age, sex, calendar time, and duration of follow-up. Follow-up was completed on October 31, 2014. Interventions: Current use of SSRIs compared with TCAs and strong compared with weak serotonin reuptake inhibitors. Main Outcomes and Measures: Incidence rate ratios (RRs) of ICH. Results: Among a cohort of 1 363 990 incident users of antidepressants (36.8% male; 63.2% female; mean [SD] age, 47.9 [18.5] years), 3036 cases of ICH were identified during follow-up and matched to 89 702 controls. Current SSRI use was associated with an increased risk for ICH (RR, 1.17; 95% CI, 1.02-1.35) relative to TCAs, highest during the first 30 days of use (RR, 1.44; 95% CI, 1.04-1.99), and translating in very few additional events. Similarly, the risk was increased by 25% with strong inhibitors (RR, 1.25; 95% CI, 1.01-1.54) and highest during the first 30 days of use (RR, 1.68; 95% CI, 0.90-3.12). Concomitant use of anticoagulants may increase the risk substantially (RR, 1.73; 95% CI, 0.89-3.39). Conclusions and Relevance: The use of SSRIs and more generally of antidepressants with strong inhibition of serotonin reuptake are associated with an increased risk for ICH, particularly in the first 30 days of use and when used concomitantly with oral anticoagulants.
Importance: Selective serotonin reuptake inhibitors (SSRIs) may increase the risk for spontaneous intracranial hemorrhage (ICH), an effect that is in theory linked to the strength of inhibition of serotonin reuptake of an antidepressant. However, whether antidepressants that are strong inhibitors of serotonin reuptake actually increase the risk for ICH and the effect of concomitant use of antithrombotics are unknown. Objectives: To assess the risk for ICH associated with the use of SSRIs compared with tricyclic antidepressants (TCAs) among new users of antidepressants and according to the relative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant use of antithrombotics modifies this risk. Design, Setting, and Participants: This population-based cohort study included new users of antidepressants 18 years or older from January 1, 1995, to June 30, 2014. More than 650 general practices in the United Kingdom contributing to the Clinical Practice Research Datalink enrolled patients. with use of a nested case-control approach, each case of a first ICH identified during follow-up was matched with as many as 30 control individuals by age, sex, calendar time, and duration of follow-up. Follow-up was completed on October 31, 2014. Interventions: Current use of SSRIs compared with TCAs and strong compared with weak serotonin reuptake inhibitors. Main Outcomes and Measures: Incidence rate ratios (RRs) of ICH. Results: Among a cohort of 1 363 990 incident users of antidepressants (36.8% male; 63.2% female; mean [SD] age, 47.9 [18.5] years), 3036 cases of ICH were identified during follow-up and matched to 89 702 controls. Current SSRI use was associated with an increased risk for ICH (RR, 1.17; 95% CI, 1.02-1.35) relative to TCAs, highest during the first 30 days of use (RR, 1.44; 95% CI, 1.04-1.99), and translating in very few additional events. Similarly, the risk was increased by 25% with strong inhibitors (RR, 1.25; 95% CI, 1.01-1.54) and highest during the first 30 days of use (RR, 1.68; 95% CI, 0.90-3.12). Concomitant use of anticoagulants may increase the risk substantially (RR, 1.73; 95% CI, 0.89-3.39). Conclusions and Relevance: The use of SSRIs and more generally of antidepressants with strong inhibition of serotonin reuptake are associated with an increased risk for ICH, particularly in the first 30 days of use and when used concomitantly with oral anticoagulants.
Authors: Rasha Alqdwah-Fattouh; Sara Rodríguez-Martín; Francisco J de Abajo; Diana González-Bermejo; Miguel Gil; Alberto García-Lledó; Francisco Bolúmar Journal: Br J Clin Pharmacol Date: 2020-05-09 Impact factor: 4.335
Authors: Alvaro Alonso; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Lindsay G S Bengtson Journal: J Cardiol Date: 2017-03-18 Impact factor: 3.159
Authors: Li Liu; Matthew Fuller; Tyler P Behymer; Yisi Ng; Thomas Christianson; Shreyansh Shah; Nicolas Kon Kam King; Daniel Woo; Michael L James Journal: Stroke Date: 2020-03-04 Impact factor: 7.914
Authors: Santo Ricceri; James W Salazar; Andrew A Vu; Eric Vittinghoff; Ellen Moffatt; Zian H Tseng Journal: J Am Coll Cardiol Date: 2021-05-18 Impact factor: 24.094